Saitama,Japan,April 25th,2017 – BushuPharmaceuticalsLimited(“Bushu”)announcesthatMr.Wes Wheeler will join the Board as a non-executive director of Bushu Pharmaceuticals Holdings Limited(“Bushu Holdings”). And he will be formally appointed in Shareholders’ meeting of Bushu Holdings which will be held in June 20th 2017.

Mr. Wheeler is currently the CEO and Chairman of Marken a leading global pharmaceutical supply chain and logistics company. Prior to Marken, Mr. Wheeler was the CEO and President of Patheon Inc., a leading global CMO. Baring Private Equity Asia (“Baring”) has been the shareholder of Bushu since acquiring 100% of the company in December 2014. Supporting further growth and globalization expansion has been a strategic priority for Bushu and Barings.

Commenting on the appointment, Jun Yokohama, CEO of Bushu, said “We look forward to having Mr. Wheeler join the Board and provide strategic advice on various initiatives including the further globalization of Bushu. His experience in leading top global pharmaceutical services companies and his top global industry contacts will be valuable to Bushu as the company continues to transform its business into a broader global platform. With the recently announced addition of Takeda Pharmaceutical Company Limited’s (“Takeda”) CMC business and ongoing partnership with Takeda, Mr. Wheeler can provide input on our strategy of leveraging off of Takeda’s development strengths.

Commenting on his appointment, Wes Wheeler said, “I am excited to be part of the Bushu team and support its further growth initiatives. Bushu has a strong reputation as the leading player in the Japan pharmaceutical CMO sector and continues to provide the highest quality service to its Japanese and multinational pharma customers. I look forward to working with Mr. Yokohama, the management team, and the shareholders Baring as they further transform Bushu with the recent addition of Takeda’s CMC business and continued growth both in Japan and overseas.

About Bushu

Bushu Pharmaceuticals Ltd. was established in August 1998 as an independent pharmaceutical contract manufacturer and today is the leading pharmaceutical CMO in the Japan market. Bushu is engaged in the pharmaceutical contract manufacturing and packaging of clinical trials and commercial products in accordance with latest GMP standards. Through the utilization of know-how and latest industry information, Bushu prides itself in being able to offer added value solutions to customers. The company operates two manufacturing facilities located in Kawagoe and Misato in Saitama prefecture. For more information, refer to our website: https://www.bushu-seiyaku.co.jp/

About Baring Private Equity Asia

Baring Private Equity Asia is one of the largest and most established independent alternative asset management firms in Asia, with total investments and committed capital of over USD 10 billion. The firm runs a pan-Asian investment program, sponsoring buyouts and providing growth capital to companies for expansion or acquisitions, as well as a private credit and a pan-Asian real estate private equity investment program. The firm has been investing in Asia since its formation in 1997 and has over 140 employees located across offices in Hong Kong, China, India, Japan and Singapore. Baring Asia currently has over 35 portfolio companies active across Asia with a total of 150,000 employees and revenue of approximately $31 billion in 2015. For more information, please visit www.bpeasia.com.